Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study

• Published in: Multiple sclerosis Vol. 12; no. 2; pp. 180 - 186
• Main Authors: Miller, D M, Cohen, J A, Kooijmans, M, Tsao, E, Cutter, G, Baier, M
• Format: Journal Article
• Language: English
• Published: Thousand Oaks, CA SAGE Publications 01.04.2006; Arnold; Sage Publications Ltd
• Subjects: Adult; Age of Onset; Biological and medical sciences; Canada; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Disability Evaluation; Disease Progression; Europe; Fatigue; Female; Humans; Immunomodulators; Male; Medical sciences; Mental Health; Middle Aged; Multiple Sclerosis - physiopathology; Multiple Sclerosis - psychology; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neurology; Pain Measurement; Pharmacology. Drug treatments; Quality of Life; Surveys and Questionnaires; Canada; Europe; Multiple Sclerosis Functional Composite; clinical trials; quality of life; Multiple Sclerosis Quality of Life Inventory; multiple sclerosis; Human; Multiple sclerosis; Nervous system diseases; Linear regression; Inflammatory disease; Quality of life; Disability; English; Weekly; Central nervous system disease; Beta interferon; Placebo; Clinical trial; Degenerative disease; Inventory
• ISSN: 1352-4585; 1477-0970
• DOI: 10.1191/135248506ms1270oa

Background The IMPACT study demonstrated the benefit of interferon beta-1a (IFNβ-1a, Avonex®) two-year change in disability measured by the Multiple Sclerosis Functional Composite (MSFC) in secondary progressive multiple sclerosis (SP-MS) and health-related quality of life (HRQoL) measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI). The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures. Methods IMPACT was an international randomized, double-blind, placebo-controlled trial of SP-MS patients. As the MSQLI is only in English, this report includes US and Canadian subjects. Subjects were randomized to weekly intramuscular (im) injections of INb-1a (60 mg) or placebo for 24 months. Results At baseline and follow-up, MSQLI correlations were generally stronger with the EDSS than with the MSQLI, MSFC but comparable with MSFC components. Combining the two groups, MSQLI changes for those in the best and worst MSFC change quartiles demonstrated a statistical difference for six of the 11 MSQLI scales. Linear regression demonstrated that EDSS change from baseline to month-24 scores was correlated with change in two MSQLI components. Conclusion These data support the appropriateness of using the MSQLI with individuals who have SP-MS.